Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:

NCT ID: NCT02242253 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 2003
Phase: Phase 2
Study type: Interventional

Main Study: To evaluate and to compare the lung function response to the free combinations of tiotropium 18 μg (QD) + salmeterol 50 μg (QD or BID), salmeterol 50 μg BID and tiotropium 18 μg QD at the end of 6-week treatment periods in patients with COPD. Sub-Study: Was performed in subset of patients participating in the Main Study to assess the effect of the four randomised treatments on dynamic hyperinflation. Extension Study: To establish whether the FEV1 time profile following combination bronchodilator therapy of tiotropium plus salmeterol is affected by the pharmaceutical formulation of salmeterol, i.e. the MDI or the Diskus®.

NCT ID: NCT02242240 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: March 2001
Phase: Phase 2
Study type: Interventional

Study to establish the lung function effects of added formoterol (12μg QD and BID) during 2-week periods to pharmacodynamic steady state of tiotropium(18μg QD)

NCT ID: NCT02242227 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 2005
Phase: Phase 2
Study type: Interventional

The primary objective of this trial was to establish non-inferiority of lung function response to 25 μg salmeterol, administered as the xinafoate salt, in an inhalation powder delivered from hard polyethylene (PE) capsules via the HandiHaler® 2 compared to Serevent® Diskus® (salmeterol 50 μg, administered as the xinafoate salt) following single dose inhalation in patients with COPD. The secondary objectives were to characterize the pharmacokinetics of salmeterol inhalation powder delivered by HandiHaler® 2 from the PE hard capsule and salmeterol xinafoate delivered by Serevent® Diskus®, and to compare the safety of the two pharmaceutical forms.

NCT ID: NCT02238197 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease

Start date: February 2001
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238184 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)

Start date: January 2001
Phase: N/A
Study type: Observational

To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238171 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Start date: April 2000
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238158 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Start date: September 1999
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238145 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

Start date: January 1999
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice

NCT ID: NCT02238132 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease

Start date: December 1998
Phase: N/A
Study type: Observational

To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

NCT ID: NCT02238119 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: February 2002
Phase: Phase 2
Study type: Interventional

Study to evaluate the lung function response to the free once-daily combination of tiotropium + formoterol compared to formoterol BID and tiotropium QD